Meng Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meng Yang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Chunna Gao
School of Medicine Shanghai East Hospital Tongji University Shanghai China
1 shared publication- Fuqiang Xu
State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, Wuhan Center for Magnetic Resonance, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan, China
1 shared publication Guojun Miao
School of Medicine Shanghai East Hospital Tongji University Shanghai China
1 shared publication- Li Wang
School of Medicine, Jingchu University of Technology, Jingmen 448000, China
1 shared publication - Qing Liu
University of Chinese Academy of Sciences Beijing China
1 shared publication - Wenwen Ding
School of Medicine Jingchu University of Technology Jingmen China
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Wiley in Advanced Materials Technologies
- Vol. 11 (20) , e71252
Functionalized Design of Electrochemical Biosensing Technologies for Intelligent Healthcare
Electrochemical biosensing technologies offer an important route toward continuous and body‐interfaced health monitoring, but their translational value cannot be judged by analytical sensitivity, miniaturization, or device integration alone. This Review presents functionalized design as an application‐backward, cross‐scale framework that links clinical needs and biomarker–matrix constraints with recognition chemistry, biointerfaces, functional materials, transduction architectures, calibration, data interpretation, manufacturability, and validation. We first define this framework and examine platform‐level opportunities and failure modes across wearable, minimally invasive transdermal, implantable, and complementary transistor‐based systems. We then discuss how biomarker class, matrix accessibility, temporal dynamics, and clinical role determine sensing requirements, before evaluating representative technologies across four task‐defined scenarios: longitudinal monitoring, early molecular detection and risk stratification, continuous sensing in difficult physiological environments, and diagnosis‐linked wound management. Finally, we assess data intelligence and translation with emphasis on data quality, model robustness, interpretability, technology readiness, manufacturing reproducibility, clinical utility, regulation, and deployment. By distinguishing proof‐of‐concept performance from evidence relevant to practical use, this review provides a design and assessment framework for advancing electrochemical biosensing toward reliable, clinically actionable healthcare systems.
- 12 August 2026
- Published by Wiley in Advanced Materials Technologies
- Vol. 11 (20) , e71252
Open AccessFunctionalized Design of Electrochemical Biosensing Technologies for Intelligent Healthcare
Electrochemical biosensing technologies offer an important route toward continuous and body‐interfaced health monitoring, but their translational value cannot be judged by analytical sensitivity, miniaturization, or device integration alone. This Review presents functionalized design as an application‐backward, cross‐scale framework that links clinical needs and biomarker–matrix constraints with recognition chemistry, biointerfaces, functional materials, transduction architectures, calibration, data interpretation, manufacturability, and validation. We first define this framework and examine platform‐level opportunities and failure modes across wearable, minimally invasive transdermal, implantable, and complementary transistor‐based systems. We then discuss how biomarker class, matrix accessibility, temporal dynamics, and clinical role determine sensing requirements, before evaluating representative technologies across four task‐defined scenarios: longitudinal monitoring, early molecular detection and risk stratification, continuous sensing in difficult physiological environments, and diagnosis‐linked wound management. Finally, we assess data intelligence and translation with emphasis on data quality, model robustness, interpretability, technology readiness, manufacturing reproducibility, clinical utility, regulation, and deployment. By distinguishing proof‐of‐concept performance from evidence relevant to practical use, this review provides a design and assessment framework for advancing electrochemical biosensing toward reliable, clinically actionable healthcare systems.
- Open Access
- 4 December 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (12) , e70686
Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions
Background: Drug‐resistant epilepsy (DRE) affects nearly one‐third of patients and remains a major unmet clinical need, despite advances in anti‐seizure medications (ASMs). Carbogen, a low‐concentration carbon dioxide (CO 2 ) and oxygen (O 2 ) gas mixture, has reemerged as a physiology‐based therapy owing to renewed insights into pH‐sensitive seizure mechanisms. Methods: This review summarizes preclinical and clinical evidence on carbogen inhalation for seizure control. Mechanistic data on pH‐dependent ion channels, GABAergic inhibition, and adenosine signaling were condensed, and clinical outcomes across seizure types and inhalation protocols were compared for safety and efficacy. Results: Carbogen induces short‐term respiratory acidosis, lowering brain extracellular pH to activate acid‐sensitive ion channels (e.g., ASIC1a and NaV1.2), enhance GABAergic inhibition, and boost adenosine signaling. These effects are rapid, reversible, and distinct from conventional ASMs. Preclinical studies show strong seizure suppression, especially under hyperventilation‐induced alkalosis. Clinically, brief low‐dose inhalation (5% CO 2 for ≤ 3 min) is effective and well tolerated in focal and absence seizures, whereas earlier high‐concentration protocols caused adverse effects. Efficacy varies by seizure type: benefits in nonconvulsive status epilepticus (NCSE) are limited, and the CARDIF trial found no advantage for pediatric febrile seizures. Ongoing work, such as the CRESCENT trial, is exploring carbogen as an adjunct therapy for pediatric convulsive status epilepticus (CSE). Conclusions: Evidence supports carbogen's therapeutic promise and highlights the need for precise patient selection, controlled delivery, and comprehensive safety testing. Future research should develop biomarker‐guided, closed‐loop systems and test synergy with established ASMs to advance carbogen as a mechanism‐based therapy within precision epilepsy care.
- 4 December 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (12) , e70686
Open AccessCarbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions
Background: Drug‐resistant epilepsy (DRE) affects nearly one‐third of patients and remains a major unmet clinical need, despite advances in anti‐seizure medications (ASMs). Carbogen, a low‐concentration carbon dioxide (CO 2 ) and oxygen (O 2 ) gas mixture, has reemerged as a physiology‐based therapy owing to renewed insights into pH‐sensitive seizure mechanisms. Methods: This review summarizes preclinical and clinical evidence on carbogen inhalation for seizure control. Mechanistic data on pH‐dependent ion channels, GABAergic inhibition, and adenosine signaling were condensed, and clinical outcomes across seizure types and inhalation protocols were compared for safety and efficacy. Results: Carbogen induces short‐term respiratory acidosis, lowering brain extracellular pH to activate acid‐sensitive ion channels (e.g., ASIC1a and NaV1.2), enhance GABAergic inhibition, and boost adenosine signaling. These effects are rapid, reversible, and distinct from conventional ASMs. Preclinical studies show strong seizure suppression, especially under hyperventilation‐induced alkalosis. Clinically, brief low‐dose inhalation (5% CO 2 for ≤ 3 min) is effective and well tolerated in focal and absence seizures, whereas earlier high‐concentration protocols caused adverse effects. Efficacy varies by seizure type: benefits in nonconvulsive status epilepticus (NCSE) are limited, and the CARDIF trial found no advantage for pediatric febrile seizures. Ongoing work, such as the CRESCENT trial, is exploring carbogen as an adjunct therapy for pediatric convulsive status epilepticus (CSE). Conclusions: Evidence supports carbogen's therapeutic promise and highlights the need for precise patient selection, controlled delivery, and comprehensive safety testing. Future research should develop biomarker‐guided, closed‐loop systems and test synergy with established ASMs to advance carbogen as a mechanism‐based therapy within precision epilepsy care.